Comment on Hadadi et al., Does recombinant human erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects? J. Med. Virol. 2020; 92:915-918.
作者信息
Gando Alejandro, Alexay Sofia, Galán Núñez Juan P, Cano Lucía N, Diez Roberto A, Costa Luis A
机构信息
Departamento de Docencia e Investigación, Hospital Sirio Libanés, Buenos Aires, Argentina.
Laboratorio de Virología, Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina.
出版信息
J Med Virol. 2021 May;93(5):2626-2627. doi: 10.1002/jmv.26879. Epub 2021 Mar 1.
Abstract
摘要
相似文献
1
Comment on Hadadi et al., Does recombinant human erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects? J. Med. Virol. 2020; 92:915-918.对哈达迪等人的评论，《重症新型冠状病毒肺炎患者使用重组人促红细胞生成素是否具有神奇的治疗效果？》，《医学病毒学杂志》2020年；92:915 - 918。
J Med Virol. 2021 May;93(5):2626-2627. doi: 10.1002/jmv.26879. Epub 2021 Mar 1.
2
Does recombinant human erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects?危重症 COVID-19 患者应用重组人促红细胞生成素治疗有神奇疗效吗？
J Med Virol. 2020 Jul;92(7):915-918. doi: 10.1002/jmv.25839. Epub 2020 Apr 19.
3
In critically ill patients with COVID-19, therapeutic anticoagulation did not increase organ support-free days.在 COVID-19 重症患者中，治疗性抗凝并未增加无器官支持天数。
Ann Intern Med. 2021 Dec;174(12):JC135. doi: 10.7326/ACPJ202112210-135. Epub 2021 Dec 7.
4
Best practice statements and recommendations for caring for critically ill patients with COVID-19.关于照顾 COVID-19 重症患者的最佳实践声明和建议。
Ann Intern Med. 2020 Jun 16;172(12):JC62. doi: 10.7326/ACPJ202006160-062.
5
Re: 'Clinical course and outcomes of critically ill patients with COVID-19 infection: a systematic review' by Serafim et al.关于：Serafim等人的《COVID-19感染重症患者的临床病程及结局：一项系统评价》
Clin Microbiol Infect. 2021 Jun;27(6):938-939. doi: 10.1016/j.cmi.2021.01.010. Epub 2021 Jan 21.
6
Comment on: "Care for critically ill patients with COVID-19: don't forget the eyes".
Eye (Lond). 2021 Jun;35(6):1775-1776. doi: 10.1038/s41433-020-1079-6. Epub 2020 Jul 13.
7
Re: "High prevalence of heterotopic ossification in critically ill patients with severe COVID-19" by Stoira et al.关于：斯托伊拉等人所著的《重症新型冠状病毒肺炎患者中异位骨化的高患病率》
Clin Microbiol Infect. 2021 Jul;27(7):1051-1052. doi: 10.1016/j.cmi.2020.12.038. Epub 2021 Jan 15.
8
Letter to the Editor in response to Chen et al. 2020.致编辑的信，回应陈等人 2020 年的文章。
Respir Res. 2020 Nov 30;21(1):315. doi: 10.1186/s12931-020-01548-0.
9
Comment to: Intensive support recommendations for critically-ill patients with suspected or confirmed COVID-19 infection.对《疑似或确诊新型冠状病毒肺炎感染重症患者的强化支持建议》的评论
Einstein (Sao Paulo). 2020;18:eCE5931. doi: 10.31744/einstein_journal/2020ce5931. Epub 2020 Aug 5.
10
Letter in response to: Alamer A, Alrashed AA, Alfaifi M, et al. Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis. Curr Med Res Opin. 2021;19:1-13. DOI: 10.1080/03007995.2021.1920900.回复信：针对阿拉默·A、阿尔拉希德·AA、阿尔法菲·M等人的研究。与支持性治疗相比，法匹拉韦在中度至重度新冠肺炎患者中的有效性和安全性：一项倾向评分匹配敏感性分析的回顾性研究。《当前医学研究与观点》。2021年；19:1 - 13。DOI: 10.1080/03007995.2021.1920900
Curr Med Res Opin. 2022 Mar;38(3):355-356. doi: 10.1080/03007995.2021.2020463. Epub 2021 Dec 31.
本文引用的文献
1
Host Genetics at the Intersection of Autoimmunity and COVID-19: A Potential Key for Heterogeneous COVID-19 Severity.宿主遗传学在自身免疫与 COVID-19 中的交汇：COVID-19 严重程度异质性的潜在关键。
Front Immunol. 2020 Dec 22;11:586111. doi: 10.3389/fimmu.2020.586111. eCollection 2020.
2
US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2.美国疾病控制与预防中心实时逆转录聚合酶链反应检测试剂盒，用于检测严重急性呼吸综合征冠状病毒 2。
Emerg Infect Dis. 2020 Aug;26(8):1654-65. doi: 10.3201/eid2608.201246. Epub 2020 May 15.
3
Does recombinant human erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects?危重症 COVID-19 患者应用重组人促红细胞生成素治疗有神奇疗效吗？
J Med Virol. 2020 Jul;92(7):915-918. doi: 10.1002/jmv.25839. Epub 2020 Apr 19.
Zotero 插件